Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort.

Kévin BigautThibaut FabacherLaurent KremerJean-Claude OngagnaArnaud KwiatkowskiFrançois SellalDidier FerribySylvie CourtoisPatrick VermerschNicolas CollonguesHélène ZéphirJérôme De SezeOlivier Outteryck

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2020)

In our cohort of patients treated with NTZ, poor outcomes were infrequent and are driven by disease activity.

Keyphrases

disease activity
rheumatoid arthritis
systemic lupus erythematosus
rheumatoid arthritis patients
ankylosing spondylitis
multiple sclerosis
juvenile idiopathic arthritis
metabolic syndrome